XML 107 R7.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
9 Months Ended
Mar. 31, 2020
Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income (loss) attributable to Myriad Genetics, Inc. stockholders $ (144.1) $ 8.8
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Depreciation and amortization 54.3 54.6
Non-cash interest expense 0.3 0.3
Gain on deconsolidation of subsidiary (1.0)  
Gain on disposition of assets (0.2) (0.9)
Share-based compensation expense 23.3 24.7
Deferred income taxes (22.9) 3.0
Unrecognized tax benefits 0.6 (7.3)
Impairment of goodwill and intangible assets 99.7  
Change in fair value of contingent consideration 2.8 (1.4)
Payment of contingent consideration   (1.5)
Changes in assets and liabilities:    
Prepaid expenses 3.5 2.0
Trade accounts receivable 29.5 (27.0)
Other receivables 0.9 (0.4)
Inventory   7.4
Prepaid taxes (0.3) (3.0)
Accounts payable (2.1) (8.1)
Accrued liabilities (15.4) 1.4
Deferred revenue 1.8 (0.4)
Net cash provided by operating activities 30.7 52.2
CASH FLOWS FROM INVESTING ACTIVITIES    
Capital expenditures (7.8) (7.2)
Acquisitions, net of cash acquired   (278.5)
Proceeds from sale of subsidiary 21.3  
Purchases of marketable investment securities (60.8) (57.0)
Proceeds from maturities and sales of marketable investment securities 56.3 51.8
Net cash provided by (used in) investing activities 9.0 (290.9)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Net proceeds from common stock issued under share-based compensation plans 1.5 6.5
Payment of contingent consideration recognized at acquisition (3.9)  
Net proceeds from revolving credit facility   340.0
Repayment of revolving credit facility (8.6) (85.0)
Fees associated with refinancing of revolving credit facility   (1.4)
Repurchase and retirement of common stock   (50.0)
Net cash provided by (used in) financing activities (11.0) 210.1
Effect of foreign exchange rates on cash and cash equivalents (0.9) 2.6
Net increase (decrease) in cash and cash equivalents 27.8 (26.0)
Cash and cash equivalents at beginning of the period 93.2 110.9
Cash and cash equivalents at end of the period $ 121.0 $ 84.9